Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
- 9 December 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (24), 5126-5129
- https://doi.org/10.1182/blood-2010-06-290668
Abstract
Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was λ in 72% patients, and κ in 28% patients. κ-AL had more GI tract and liver involvement, where as renal involvement was more with λ-AL. While the overall survival (OS) was similar for κ and λ-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC−uninvolved FLC; κ > 29.4 mg/dL or λ > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL.This publication has 26 references indexed in Scilit:
- Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myelomaLeukemia, 2010
- Translocation t(11;14) and survival of patients with light chain (AL) amyloidosisHaematologica, 2009
- Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemLeukemia, 2008
- Evaluation of the serum-free light chain test in untreated patients with AL amyloidosisHaematologica, 2008
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008
- Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosisInternal Medicine Journal, 2007
- AmyloidosisBest Practice & Research Clinical Haematology, 2005
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and AmyloidosisAmerican Journal of Hematology, 2005
- Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosisBone Marrow Transplantation, 2005
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958